Characteristics of registered clinical trials on traditional Chinese medicine for coronavirus disease 2019 (COVID-19): a scoping review
Characteristics of registered clinical trials on traditional Chinese medicine for coronavirus disease 2019 (COVID-19): a scoping review
Introduction: Traditional Chinese medicine (TCM) has been fully committed to the treatment of coronavirus disease 2019 (COVID-19) in China. An increasing number of clinical trials have been registered to evaluate the effects of TCM for COVID-19. The aim of this study was to review the existing TCM clinical trial registrations and identify potentially promising and available TCM therapies, in order to provide a reference for the global management of COVID-19. Methods: All clinical trials on TCM for COVID-19 registered in registry platforms worldwide were searched. The data of registration temporal trend, design, objective, interventions, and relevant information were reviewed and summarized. Results: 161 TCM trials were identified from three registries (January 26 to May 14 2020,). Of these, 94 (58.4%) were randomized controlled trials and 114 trials (70.8%) assessed therapeutic effects; while the remainder focused on prevention, rehabilitation, and the epidemiology of TCM syndromes. Eight trials (5.0%) had completed their recruitment. TCM interventions with potential for further evaluation in terms of prevention were moxibustion, Huoxiang Zhengqi pill and Jinye Baidu granules. For treatment of COVID-19, Qingfei Paidu decoction, Huashi Baidu decoction, Lianhua Qingwen capsules, Toujie Quwen granules and Xiyanping injection, and Xuebijing injection were to be tested for their therapeutic effects and symptoms relief. For rehabilitation, Tai Chi and Liuzijue were to be tested for improving patients’ lung function. Conclusion: Some potentially promising TCM interventions have been identified and deserve further evaluation to establish their evidence base, particularly on populations outside of China.
Chinese medicine, Clinical trial protocol, COVID-19 drug treatment, Lianhua Qingwen capsules, Medicine, Qingfei paidu decoction, Randomized controlled trial
Luo, Hui
8714682c-b7ba-4537-a1ae-10dc979a0960
Yang, Ming
78baa1bf-1deb-4f11-bec1-8291ae52fa86
Tang, Qiao Ling
f211d6e2-764d-47cd-84cc-1d8d35220887
Hu, Xiao Yang
65904b24-3775-4b14-9532-eb703a056655
Willcox, Merlin L.
dad5b622-9ac2-417d-9b2e-aad41b64ffea
Liu, Jian Ping
4c1de9c3-e9c2-4d4e-a0a4-dad123a39c76
January 2021
Luo, Hui
8714682c-b7ba-4537-a1ae-10dc979a0960
Yang, Ming
78baa1bf-1deb-4f11-bec1-8291ae52fa86
Tang, Qiao Ling
f211d6e2-764d-47cd-84cc-1d8d35220887
Hu, Xiao Yang
65904b24-3775-4b14-9532-eb703a056655
Willcox, Merlin L.
dad5b622-9ac2-417d-9b2e-aad41b64ffea
Liu, Jian Ping
4c1de9c3-e9c2-4d4e-a0a4-dad123a39c76
Luo, Hui, Yang, Ming, Tang, Qiao Ling, Hu, Xiao Yang, Willcox, Merlin L. and Liu, Jian Ping
(2021)
Characteristics of registered clinical trials on traditional Chinese medicine for coronavirus disease 2019 (COVID-19): a scoping review.
European Journal of Integrative Medicine, 41 (1), [101251].
(doi:10.1016/j.eujim.2020.101251).
Abstract
Introduction: Traditional Chinese medicine (TCM) has been fully committed to the treatment of coronavirus disease 2019 (COVID-19) in China. An increasing number of clinical trials have been registered to evaluate the effects of TCM for COVID-19. The aim of this study was to review the existing TCM clinical trial registrations and identify potentially promising and available TCM therapies, in order to provide a reference for the global management of COVID-19. Methods: All clinical trials on TCM for COVID-19 registered in registry platforms worldwide were searched. The data of registration temporal trend, design, objective, interventions, and relevant information were reviewed and summarized. Results: 161 TCM trials were identified from three registries (January 26 to May 14 2020,). Of these, 94 (58.4%) were randomized controlled trials and 114 trials (70.8%) assessed therapeutic effects; while the remainder focused on prevention, rehabilitation, and the epidemiology of TCM syndromes. Eight trials (5.0%) had completed their recruitment. TCM interventions with potential for further evaluation in terms of prevention were moxibustion, Huoxiang Zhengqi pill and Jinye Baidu granules. For treatment of COVID-19, Qingfei Paidu decoction, Huashi Baidu decoction, Lianhua Qingwen capsules, Toujie Quwen granules and Xiyanping injection, and Xuebijing injection were to be tested for their therapeutic effects and symptoms relief. For rehabilitation, Tai Chi and Liuzijue were to be tested for improving patients’ lung function. Conclusion: Some potentially promising TCM interventions have been identified and deserve further evaluation to establish their evidence base, particularly on populations outside of China.
This record has no associated files available for download.
More information
Accepted/In Press date: 1 November 2020
e-pub ahead of print date: 12 November 2020
Published date: January 2021
Keywords:
Chinese medicine, Clinical trial protocol, COVID-19 drug treatment, Lianhua Qingwen capsules, Medicine, Qingfei paidu decoction, Randomized controlled trial
Identifiers
Local EPrints ID: 449145
URI: http://eprints.soton.ac.uk/id/eprint/449145
ISSN: 1876-3820
PURE UUID: 41d4a1d2-bf5a-4709-a1f9-a72706fa7ab3
Catalogue record
Date deposited: 18 May 2021 16:31
Last modified: 18 Nov 2022 02:47
Export record
Altmetrics
Contributors
Author:
Hui Luo
Author:
Ming Yang
Author:
Qiao Ling Tang
Author:
Jian Ping Liu
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
